問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Urology

Division of Colorectal Surgery

Division of General Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital
Taipei Veterans General Hospital

更新時間：2023-09-19

蘇祐立Su, Yu-Li
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

  • yolisu@cgmh.org.tw

Recruiting Trial

100Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇祐立

List

194Cases

2015-01-15 - 2023-06-06

Phase III

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer.

  • Condition/Disease

    hormone receptor positive, HER2-negative, advanced breast cancer.

  • Test Drug

    LEE011

Participate Sites
8Sites

Terminated8Sites

2015-09-01 - 2021-02-19

Phase II

A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment.

  • Condition/Disease

    moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma

  • Test Drug

    PDR001

Participate Sites
4Sites

Not yet recruiting1Sites

Terminated3Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-10-01 - 2020-04-30

Phase III

SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor (AI) treatment

  • Condition/Disease

    hormone receptor positive, HER2-negative advanced breast cancer

  • Test Drug

    BYL719/Faslodex

Participate Sites
3Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

2014-02-01 - 2016-05-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2012-05-15 - 2020-09-08

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-08-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-09-01 - 2018-12-18

Phase III

A phase III randomized, double blind placebo controlled study of oral BKM120 in combination with fulvestrant, in the treatment of postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer whose disease has progressed on or after aromatase inhibitor treatment

  • Condition/Disease

    locally advanced or metastatic breast cancer

  • Test Drug

    BKM120

Participate Sites
5Sites

Terminated5Sites

2019-02-28 - 2023-04-30

Phase II

A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

  • Condition/Disease

    Breast cancer

  • Test Drug

    KISQALI

Participate Sites
9Sites

Recruiting8Sites

劉良智
China Medical University Hospital-Taipei

未分科

陳訓徹
Linkou Chang Gung Medical Foundation

2018-08-18 - 2022-07-11

Phase III

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1

  • Condition/Disease

    Untreated Advanced Gastric and Gastroesophageal Cancer

  • Test Drug

    FPA144

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated4Sites

白禮源
China Medical University Hospital-Taipei

未分科

2015-07-01 - 2026-05-29

Phase III

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence

  • Condition/Disease

    Melanoma

  • Test Drug

    Nivolumab, Ipilimumab

Participate Sites
4Sites

Terminated3Sites

林振源
China Medical University Hospital-Taipei

未分科

林振源
China Medical University Hospital

Division of Hematology & Oncology

1 16 17 18 19 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB